Cost-effectiveness of guideline-based stepped and collaborative care versus treatment as usual for patients with depression - a cluster-randomized trial

Christian Brettschneider, Daniela Heddaeus, Maya Steinmann, Martin Härter, Birgit Watzke, Hans-Helmut König, Christian Brettschneider, Daniela Heddaeus, Maya Steinmann, Martin Härter, Birgit Watzke, Hans-Helmut König

Abstract

Background: Depression is associated with major patient burden. Its treatment requires complex and collaborative approaches. A stepped care model based on the German National Clinical Practice Guideline "Unipolar Depression" has been shown to be effective. In this study we assess the cost-effectiveness of this guideline based stepped care model versus treatment as usual in depression.

Methods: This prospective cluster-randomized controlled trial included 737 depressive adult patients. Primary care practices were randomized to an intervention (IG) or a control group (CG). The intervention consisted of a four-level stepped care model. The CG received treatment as usual. A cost-utility analysis from the societal perspective with a time horizon of 12 months was performed. We used quality-adjusted life years (QALY) based on the EQ-5D-3L as effect measure. Resource utilization was assessed by patient questionnaires. Missing values were imputed by 'multiple imputation using chained equations' based on predictive mean matching. We calculated adjusted group differences in costs and effects as well as incremental cost-effectiveness ratios. To describe the statistical and decision uncertainty cost-effectiveness acceptability curves were constructed based on net-benefit regressions with bootstrapped standard errors (1000 replications). The complete sample and subgroups based on depression severity were considered.

Results: We found no statically significant differences in costs and effects between IG and CG. The incremental total societal costs (+€5016; 95%-CI: [-€259;€10,290) and effects (+ 0.008 QALY; 95%-CI: [- 0.030; 0.046]) were higher in the IG in comparison to the CG. Significantly higher costs were found in the IG for outpatient physician services and psychiatrist services in comparison to the CG. Significantly higher total costs and productivity losses in the IG in comparison to the CG were found in the group with severe depression. Incremental cost-effectiveness ratios for the IG in comparison to the CG were unfavourable (complete sample: €627.000/QALY gained; mild depression: dominated; moderately severe depression: €645.154/QALY gained; severe depression: €2082,714/QALY gained) and the probability of cost-effectiveness of the intervention was low, except for the group with moderate depression (ICER: dominance; 70% for willingness-to-pay threshold of €50,000/QALY gained).

Conclusions: We found no evidence for cost-effectiveness of the intervention in comparison to treatment as usual.

Trial registration: NCT, NCT01731717 . Registered 22 November 2012 - Retrospectively registered.

Keywords: Costs and cost analysis; Delivery of healthcare, integrated; Depressive disorder; Quality-adjusted life years.

Conflict of interest statement

Christian Brettschneider is an Associate Editor of BMC Psychiatry. All other authors declare that there are no competing interests.

Figures

Fig. 1
Fig. 1
Cost-effectiveness acceptability curves for the complete sample and the subgroups by depression severity

References

    1. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–679.
    1. Duhoux A, Fournier L, Gauvin L, Roberge P. Quality of care for major depression and its determinants: a multilevel analysis. BMC Psychiatry. 2012;12:142.
    1. Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci. 2011;13(1):7–23.
    1. Jacobi F, Höfler M, Meister W, Wittchen HU. Prevalence, detection and prescribing behavior in depressive syndromes. A German federal family physician study. Nervenarzt. 2002;73(7):651–658.
    1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2163–2196.
    1. Stafford L, Berk M, Reddy P, Jackson HJ. Comorbid depression and health-related quality of life in patients with coronary artery disease. J Psychosom Res. 2007;62(4):401–410.
    1. Leung YW, Flora DB, Gravely S, Irvine J, Carney RM, Grace SL. The impact of premorbid and postmorbid depression onset on mortality and cardiac morbidity among patients with coronary heart disease: meta-analysis. Psychosom Med. 2012;74(8):786–801.
    1. Cuijpers P, Vogelzangs N, Twisk J, Kleiboer A, Li J, Penninx BW. Differential mortality rates in major and subthreshold depression: meta-analysis of studies that measured both. Br J Psychiatry : the journal of mental science. 2013;202(1):22–27.
    1. Luppa M, Heinrich S, Angermeyer MC, Konig HH, Riedel-Heller SG. Cost-of-illness studies of depression: a systematic review. J Affect Disord. 2007;98(1–2):29–43.
    1. DGPPN B, KBV, AWMF (Hrsg.) für die Leitliniengruppe Unipolare Depression,. S3-Leitlinie/Nationale Versor-gungsLeitlinie Unipolare Depression – Langfassung Berlin: DGPPN, BÄK, KBV, AWMF; 2015 [2:[Available from: .
    1. Härter M, Bermejo I, Ollenschläger G, Schneider F, Gaebel W, Hegerl U, et al. Improving quality of care for depression: the German action Programme for the implementation of evidence-based guidelines. Int J Qual Health Care. 2006;18(2):113–119.
    1. Bower P, Gilbody S. Stepped care in psychological therapies: access, effectiveness and efficiency. Narrative literature review. Br J Psychiatry : the journal of mental science. 2005;186:11–17.
    1. Firth N, Barkham M, Kellett S. The clinical effectiveness of stepped care systems for depression in working age adults: a systematic review. J Affect Disord. 2015;170:119–130.
    1. van Straten A, Hill J, Richards DA, Cuijpers P. Stepped care treatment delivery for depression: a systematic review and meta-analysis. Psychol Med. 2015;45(2):231–246.
    1. Richards D, Enrique A, Eilert N, Franklin M, Palacios J, Duffy D, et al. A pragmatic randomized waitlist-controlled effectiveness and cost-effectiveness trial of digital interventions for depression and anxiety. NPJ Digit Med. 2020;3:85.
    1. Duarte A, Walker S, Littlewood E, Brabyn S, Hewitt C, Gilbody S, et al. Cost-effectiveness of computerized cognitive-behavioural therapy for the treatment of depression in primary care: findings from the randomised evaluation of the effectiveness and acceptability of computerised therapy (REEACT) trial. Psychol Med. 2017;47(10):1825–1835.
    1. Solomon D, Proudfoot J, Clarke J, Christensen H. E-CBT (myCompass), antidepressant medication, and face-to-face psychological treatment for depression in Australia: a cost-effectiveness comparison. J Med Internet Res. 2015;17(11):e255.
    1. Kaltenthaler E, Brazier J, De Nigris E, Tumur I, Ferriter M, Beverley C, et al. Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation. Health Technol Assess (Winchester, England) 2006;10(33):1–168.
    1. El Alili M, Schuurhuizen C, Braamse AMJ, Beekman ATF, van der Linden MH, Konings IR, et al. Economic evaluation of a combined screening and stepped-care treatment program targeting psychological distress in patients with metastatic colorectal cancer: a cluster randomized controlled trial. Palliat Med. 2020;34(7):934–945.
    1. Painter JT, Fortney JC, Gifford AL, Rimland D, Monson T, Rodriguez-Barradas MC, et al. Cost-Effectiveness of Collaborative Care for Depression in HIV Clinics. J Acquired Immune Deficiency Syndromes (1999) 2015;70(4):377–385.
    1. Simon GE, Katon WJ, Lin EH, Rutter C, Manning WG, Von Korff M, et al. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. Arch Gen Psychiatry. 2007;64(1):65–72.
    1. Fitzgibbon KP, Plett D, Chan BCF, Hancock-Howard R, Coyte PC, Blumberger DM. Cost-utility analysis of electroconvulsive therapy and repetitive Transcranial magnetic stimulation for treatment-resistant depression in Ontario. Can J Psychiatry. 2020;65(3):164–173.
    1. Barnett PG, Wong W, Hall S. The cost-effectiveness of a smoking cessation program for out-patients in treatment for depression. Addiction (Abingdon, England) 2008;103(5):834–840.
    1. Grochtdreis T, Brettschneider C, Bjerregaard F, Bleich C, Boczor S, Härter M, et al. Cost-effectiveness analysis of collaborative treatment of late-life depression in primary care (GermanIMPACT) Eur Psychiatry : the journal of the Association of European Psychiatrists. 2019;57:10–18.
    1. Lavelle TA, Kommareddi M, Jaycox LH, Belsher B, Freed MC, Engel CC. Cost-effectiveness of collaborative care for depression and PTSD in military personnel. Am J Manag Care. 2018;24(2):91–98.
    1. van der Weele GM, de Waal MW, van den Hout WB, van der Mast RC, de Craen AJ, Assendelft WJ, et al. Yield and costs of direct and stepped screening for depressive symptoms in subjects aged 75 years and over in general practice. Int J Geriatric Psychiatry. 2011;26(3):229–238.
    1. Siskind D, Araya R, Kim J. Cost-effectiveness of improved primary care treatment of depression in women in Chile. Br J Psychiatry : the journal of mental science. 2010;197(4):291–296.
    1. Araya R, Flynn T, Rojas G, Fritsch R, Simon G. Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile. Am J Psychiatry. 2006;163(8):1379–1387.
    1. Pyne JM, Fortney JC, Tripathi SP, Maciejewski ML, Edlund MJ, Williams DK. Cost-effectiveness analysis of a rural telemedicine collaborative care intervention for depression. Arch Gen Psychiatry. 2010;67(8):812–821.
    1. Stevenson MD, Scope A, Sutcliffe PA, Booth A, Slade P, Parry G, et al. Group cognitive behavioural therapy for postnatal depression: a systematic review of clinical effectiveness, cost-effectiveness and value of information analyses. Health Technol Assess (Winchester, England) 2010;14(44):1–107.
    1. Simon GE, Katon WJ, VonKorff M, Unützer J, Lin EH, Walker EA, et al. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Am J Psychiatry. 2001;158(10):1638–1644.
    1. Yan C, Rittenbach K, Souri S, Silverstone PH. Cost-effectiveness analysis of a randomized study of depression treatment options in primary care suggests stepped-care treatment may have economic benefits. BMC Psychiatry. 2019;19(1):240.
    1. Meeuwissen JAC, Feenstra TL, Smit F, Blankers M, Spijker J, Bockting CLH, et al. The cost-utility of stepped-care algorithms according to depression guideline recommendations - results of a state-transition model analysis. J Affect Disord. 2019;242:244–254.
    1. Härter M, Watzke B, Daubmann A, Wegscheider K, König HH, Brettschneider C, et al. Guideline-based stepped and collaborative care for patients with depression in a cluster-randomised trial. Sci Rep. 2018;8(1):9389.
    1. Watzke B, Heddaeus D, Steinmann M, König HH, Wegscheider K, Schulz H, et al. Effectiveness and cost-effectiveness of a guideline-based stepped care model for patients with depression: study protocol of a cluster-randomized controlled trial in routine care. BMC Psychiatry. 2014;14:230.
    1. Fydrich T, Sommer G, Tydecks S, Brähler E. Fragebogen zur sozialen Unterstützung (F-SozU): Normierung der Kurzform (K-14) Z Med Psychol. 2009;18(1):43–48.
    1. Löwe B, Spitzer RL, Zipfel J, Herzog W. PHQ-D Gesundheitsfragebogen für Patienten; Manual und Kurzform. Karlsruhe: Pfizer; 2002.
    1. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613.
    1. Bullinger M. German translation and psychometric testing of the SF-36 health survey: preliminary results from the IQOLA project. Soc Sci Med. 1995;41(10):1359–1366.
    1. Ware J, Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233.
    1. Wirtz MA, Morfeld M, Glaesmer H, Brähler E. Konfirmatorische Prüfung der Skalenstruktur des SF-12 Version 2.0 in einer deutschen bevölkerungs-repräsentativen Stichprobe. Diagnostica. 2018;64:84–96.
    1. EuroQol Group EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.
    1. Roick C, Kilian R, Matschinger H, Bernert S, Mory C, Angermeyer MC. German adaptation of the client sociodemographic and service receipt inventory - an instrument for the cost of mental health care. Psychiatrische Praxis. 2001;Suppl 2:S84–S90.
    1. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–1108.
    1. Greiner W, Claes C, Busschbach JJ, von der Schulenburg JM. Validating the EQ-5D with time trade off for the German population. Eur J Health Economics : HEPAC : health economics in prevention and care. 2005;6(2):124–130.
    1. König HH, Born A, Heider D, Matschinger H, Heinrich S, Riedel-Heller SG, et al. Cost-effectiveness of a primary care model for anxiety disorders. Br J Psychiatry : the journal of mental science. 2009;195(4):308–317.
    1. Arnold M, Pfeifer K, Quante AS. Is risk-stratified breast cancer screening economically efficient in Germany? PLoS One. 2019;14(5):e0217213.
    1. Norström F, Waenerlund AK, Lindholm L, Nygren R, Sahlén KG, Brydsten A. Does unemployment contribute to poorer health-related quality of life among Swedish adults? BMC Public Health. 2019;19(1):457.
    1. Sapin C, Fantino B, Nowicki ML, Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes. 2004;2:20.
    1. König HH, Bernert S, Angermeyer MC. Measuring preferences for depressive health states. Psychiatr Prax. 2005;32(3):122–131.
    1. Bock JO, Brettschneider C, Seidl H, Bowles D, Holle R, Greiner W, et al. Calculation of standardised unit costs from a societal perspective for health economic evaluation. Gesundheitswesen. 2015;77(1):53–61.
    1. Rote Liste Service GmbH . Rote Liste 2012. Frankfurt/Main: Rote Liste Service GmbH; 2012.
    1. German Statistical Office. Earnings and labour costs Wiesbaden: German Statistical Office; 2012 [Available from: .
    1. Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann. 2002;32:509–521.
    1. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res. 2011;20:40–49.
    1. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30:37–399.
    1. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 2004.
    1. van Buuren S, Brand JPL, Groothuis-Oudshoorn CGM, Rubin DB. Fully conditional specification in multivariate imputation. J Stat Comput Simul. 2006;76(12):1049–1064.
    1. van Buuren S. Flexible imputation of missing data. Boca Raton: CRC press; 2012.
    1. Barrett S, Begg S, O'Halloran P, Kingsley M. Cost-effectiveness of telephone coaching for physically inactive ambulatory care hospital patients: economic evaluation alongside the Healthy4U randomised controlled trial. BMJ Open. 2019;9(12):e032500.
    1. Duijzer G, Bukman AJ, Meints-Groenveld A, Haveman-Nies A, Jansen SC, Heinrich J, et al. Cost-effectiveness of the SLIMMER diabetes prevention intervention in Dutch primary health care: economic evaluation from a randomised controlled trial. BMC Health Serv Res. 2019;19(1):824.
    1. Ng-Kamstra JS, Rennert-May E, McKee J, Lundgren S, Manns B, Kirkpatrick AW. Protocol for a parallel economic evaluation of a trial comparing two surgical strategies in severe complicated intra-abdominal sepsis: the COOL-cost study. World J Emerg Surg: WJES. 2020;15(1):15.
    1. van den Brand FA, Nagelhout GE, Winkens B, Chavannes NH, van Schayck OCP, Evers S. Cost-effectiveness and cost-utility analysis of a work-place smoking cessation intervention with and without financial incentives. Addiction (Abingdon, England) 2020;115(3):534–545.
    1. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165–178.
    1. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11(5):415–430.
    1. Briggs AH, O’Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health. 2002;23:377–401.
    1. [Advisory Council on the Assessment of Developments in the Health Care Sector]. [Need-based regulation of health care provison - expert report 2018]. Bonn: [Advisory Council on the Assessment of Developments in the Health Care Sector]; 2018.
    1. Eaton WW, Shao H, Nestadt G, Lee HB, Bienvenu OJ, Zandi P. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry. 2008;65:513–520.
    1. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000;157:229–233.
    1. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54(3):216–226.
    1. Günther OH, Roick C, Angermeyer MC, König HH. The responsiveness of EQ-5D utility scores in patients with depression: a comparison with instruments measuring quality of life, psychopathology and social functioning. J Affect Disord. 2008;105(1–3):81–91.
    1. Crick K, Al Sayah F, Ohinmaa A, Johnson JA. Responsiveness of the anxiety/depression dimension of the 3- and 5-level versions of the EQ-5D in assessing mental health. Qual Life Res: an international journal of quality of life aspects of treatment, care and rehabilitation. 2018;27(6):1625–1633.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren